Skip to main content

Metamizol: Wirkmechanismen, Interaktionen und Agranulozytoserisiko

Metamizole (dipyrone): mode of action, drug–drug interactions, and risk of agranulocytosis

Der Schmerz volume 28, pages 584–590 (2014)Cite this article

Zusammenfassung

Metamizol ist als Vertreter der Pyrazolone ein Nichtopioidanalgetikum mit starker analgetischer sowie antipyretischer und spasmolytischer Wirkung. Aufgrund einer geringen Zahl von Agranulozytosen wurde die Substanz in manchen Ländern vom Markt genommen, in anderen Ländern wurde der Gebrauch stark eingeschränkt. Die vorliegende Arbeit diskutiert die Sicherheitsaspekte von Metamizol und zieht Vergleiche mit anderen Substanzen aus dem gleichen Indikationsgebiet.

Abstract

Metamizole (dipyrone) is a nonsteroidal compound with strong analgesic as well as antipyretic and spasmolytic properties. Based on a small number of cases of agranulocytosis, metamizole was withdrawn from the market in some countries. Other countries restricted its use. This paper discusses the safety aspects of metamizole and compares it with other compounds used for similar indications.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Literatur

  1. Abbate R, Gori AM, Pinto S et al (1990) Cyclooxygenase and lipoxygenase metabolite synthesis by polymorphonuclear neutrophils: in vitro effect of dipyrone. Prostaglandins Leukot Essent Fatty Acids 41:89–93

    CAS  PubMed  Article  Google Scholar 

  2. Abbott FV, Hellemans KG (2000) Phenacetin, acetaminophen and dipyrone: analgesic and rewarding effects. Behav Brain Res 112:177–186

    CAS  PubMed  Article  Google Scholar 

  3. Ajgaonkar VS, Marathe SN, Virani AR (1988) Dipyrone versus paracetamol: a double-blind study in typhoid fever. J Int Med Res 16:225–230

    CAS  PubMed  Google Scholar 

  4. Alves D, Duarte I (2002) Involvement of ATP-sensitive K(+) channels in the peripheral antinociceptive effect induced by dipyrone. Eur J Pharmacol 444:47–52

    CAS  PubMed  Article  Google Scholar 

  5. Andres E, Maloisel F (2008) Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15:15–21

    PubMed  Article  Google Scholar 

  6. Arzneimittelbrief (1987) 21:5

  7. Beirith A, Santos AR, Rodrigues AL et al (1998) Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action. Eur J Pharmacol 345:233–245

    CAS  PubMed  Article  Google Scholar 

  8. Bigal ME, Bordini CA, Speciali JG (2002) Intravenous dipyrone for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind study. Braz J Med Biol Res 35:1139–1145

    CAS  PubMed  Article  Google Scholar 

  9. Bigal ME, Bordini CA, Speciali JG (2001) Intravenous metamizol (Dipyrone) in acute migraine treatment and in episodic tension-type headache – a placebo-controlled study. Cephalalgia 21:90–95

    CAS  PubMed  Article  Google Scholar 

  10. Campos C, De Gregorio R, Garcia-Nieto R et al (1999) Regulation of cyclooxygenase activity by metamizol. Eur J Pharmacol 378:339–347

    CAS  PubMed  Article  Google Scholar 

  11. Coates TD, Boxer LA, Tirnauer JS (2014) Drug-induced neutropenia and agranulocytosis. UpToDate 22.2 – C22.60:Version 20.20

  12. Craig DG, Ford AC, Hayes PC et al (2010) Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Ther 31:1064–1076

    CAS  PubMed  Google Scholar 

  13. Cruz P, Garutti I, Diaz S et al (2002) Metamizol versus propacetamol: comparative study of the hemodynamic and antipyretic effects in critically ill patients. Rev Esp Anestesiol Reanim 49:391–396

    CAS  PubMed  Google Scholar 

  14. Edwards JE, Meseguer F, Faura C et al (2002) Single dose dipyrone for acute renal colic pain. Cochrane Database Syst Rev CD003867

  15. Eldor A, Polliack G, Vlodavsky I et al (1983) Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. Thromb Haemost 49:132–137

    CAS  PubMed  Google Scholar 

  16. Flower RJ, Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240:410–411

    CAS  PubMed  Article  Google Scholar 

  17. Geisslinger G, Peskar BA, Pallapies D et al (1996) The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. Thromb Haemost 76:592–597

    CAS  PubMed  Google Scholar 

  18. Gladtke E (1983) Use of antipyretic analgesics in the pediatric patient. Am J Med 75:121–126

    CAS  PubMed  Article  Google Scholar 

  19. Gozzoli V, Treggiari MM, Kleger GR et al (2004) Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med 30:401–407

    PubMed  Article  Google Scholar 

  20. Graff J, Arabmotlagh M, Cheung R et al (2007) Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther 29:438–447

    CAS  PubMed  Article  Google Scholar 

  21. Hernandez-Delgadillo GP, Cruz SL (2004) Dipyrone potentiates morphine-induced antinociception in dipyrone-treated and morphine-tolerant rats. Eur J Pharmacol 502:67–73

    CAS  PubMed  Article  Google Scholar 

  22. Hernandez N, Vanegas H (2001) Antinociception induced by PAG-microinjected dipyrone (metamizol) in rats: involvement of spinal endogenous opioids. Brain Res 896:175–178

    CAS  PubMed  Article  Google Scholar 

  23. Hohlfeld T, Zimmermann N, Weber AA et al (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6:166–173

    CAS  PubMed  Article  Google Scholar 

  24. Ibanez L, Vidal X, Ballarin E et al (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60:821–829

    CAS  PubMed  Article  Google Scholar 

  25. Kaufman DW, Kelly JP, Jurgelon JM et al (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 60:23–30

    CAS  PubMed  Google Scholar 

  26. Kaufman DW, Kelly JP, Levy M et al (1986) Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757

    Article  Google Scholar 

  27. Maj S, Centkowski P (2004) A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Med Sci Monit 10:PI93–PI95

    CAS  PubMed  Google Scholar 

  28. Messmann H, Andus T (Hrsg) (2012) Klinische Gastroenterologie: das Buch für Fort- und Weiterbildung; plus DVD mit über 1400 Befunden; 312 Tab. Thieme, Stuttgart

  29. Pakulska W, Czarnecka E (2002) Influence of mianserin on the antinociceptive effect of morphine, metamizol and indomethacin in mice. Pharmacol Res 46:415–423

    CAS  PubMed  Article  Google Scholar 

  30. Park BK, Pirmohamed M, Kitteringham NR (1992) Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 34:377–395

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  31. Poveda R, Planas E, Pol O et al (2003) Interaction between metamizol and tramadol in a model of acute visceral pain in rats. Eur J Pain 7:439–448

    CAS  PubMed  Article  Google Scholar 

  32. Prado J, Daza R, Chumbes O et al (2006) Antipyretic efficacy and tolerability of oral ibuprofen, oral dipyrone and intramuscular dipyrone in children: a randomized controlled trial. Sao Paulo Med J 124:135–140

    PubMed  Article  Google Scholar 

  33. Reiner M, Massera E, Magni E (1984) Nimesulide in the treatment of fever: a double-blind, crossover clinical trial. J Int Med Res 12:102–107

    CAS  PubMed  Google Scholar 

  34. Saussele T, Burk O, Blievernicht JK et al (2007) Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 82:265–274

    CAS  PubMed  Article  Google Scholar 

  35. Shimada SG, Otterness IG, Stitt JT (1994) A study of the mechanism of action of the mild analgesic dipyrone. Agents Actions 41:188–192

    CAS  PubMed  Article  Google Scholar 

  36. Siebel JS, Beirith A, Calixto JB (2004) Evidence for the involvement of metabotropic glutamatergic, neurokinin 1 receptor pathways and protein kinase C in the antinociceptive effect of dipyrone in mice. Brain Res 1003:61–67

    CAS  PubMed  Article  Google Scholar 

  37. Tortorici V, Vasquez E, Vanegas H (1996) Naloxone partial reversal of the antinociception produced by dipyrone microinjected into the periaqueductal gray of rats. Possible involvement of medullary off- and on-cells. Brain Res 725:106–110

    CAS  PubMed  Article  Google Scholar 

  38. Van Der Klauw MM, Goudsmit R, Halie MR et al (1999) A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159:369–374

    Article  Google Scholar 

  39. Vazquez E, Hernandez N, Escobar W et al (2005) Antinociception induced by intravenous dipyrone (metamizol) upon dorsal horn neurons: involvement of endogenous opioids at the periaqueductal gray matter, the nucleus raphe magnus, and the spinal cord in rats. Brain Res 1048:211–217

    CAS  PubMed  Article  Google Scholar 

  40. Verspohl EJ (2001) Analgetika mit antipyretischer und antiphlogistischer Wirkungskomponente. In: Ammon HPT (Hrsg) Arzneimittelneben- und -wechselwirkungen. W.V.G., Stuttgart

  41. Weithmann KU, Alpermann HG (1985) Biochemical and pharmacological effects of dipyrone and its metabolites in model systems related to arachidonic acid cascade. Arzneimittelforschung 35:947–952

    CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. C. Lampl erhielt Honorare für die Planung und Durchführung von Studien, Teilnahme an Advisory Board Meeting und Vorträge von den Firmen Allergan, AstraZeneca, Bayer, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Jansen-Cilag, Lilly, MSD, Menarini, Merck-Serono, Mundipharma, Pfizer und Sanofi-Aventis, Er erhielt finanzielle Unterstützung für klinische Forschung von den Firmen Allergan, AstraZeneca, Bayer, Grünenthal, Mundipharma und Pfizer. R. Likar gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Affiliations

  1. Abteilung für Neurogeriatrie und Remobilisation, Krankenhaus der Barmherzigen Schwestern Linz, Seilerstätte 4, 4020, Linz, Österreich

    C. Lampl

  2. Abteilung für Anästhesie und Intensivmedizin und ZISOP, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Österreich

    R. Likar

Authors
  1. C. Lampl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Likar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Lampl.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lampl, C., Likar, R. Metamizol: Wirkmechanismen, Interaktionen und Agranulozytoserisiko. Schmerz 28, 584–590 (2014). https://doi.org/10.1007/s00482-014-1490-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00482-014-1490-7

Schlüsselwörter

  • Analgesie
  • Antipyretischer Effekt
  • Sicherheit
  • Wirkmechanismus
  • Nebenwirkungen

Keywords

  • Analgesia
  • Antipyretic effect
  • Safety
  • Mode of action
  • Adverse effects